DDIS-06. Ku 70/80 IN GLIOMA - TARGETING WITH APTAMERS

Selective Targeting to Glioma with Nucleic Acid Aptamers

Malignant glioma is characterised by a rapid growth rate and high capacity for invasive infiltration to surrounding brain tissue; hence, diagnosis and treatment is difficult and patient survival is poor. Aptamers contribute a promising and unique technology for the in vitro imaging of live cells and tissues, with a potentially bright future in clinical diagnostics and therapeutics for malignant...

Targeting cancer with peptide aptamers

A major endeavour in cancer chemotherapy is to develop agents that specifically target a biomolecule of interest. There are two main classes of targeting agents: small molecules and biologics. Among biologics (e.g.: antibodies), DNA, RNA but also peptide aptamers are relatively recent agents. Peptide aptamers are seldom described but represent attractive agents that can inhibit a growing panel ...

Targeting of antibodies using aptamers.

Rfc 7080

The scalability of Hierarchical Virtual Private LAN Service (H-VPLS) with Ethernet access networks (RFC 4762) can be improved by incorporating Provider Backbone Bridge functionality in the VPLS access. Provider Backbone Bridging has been standardized as IEEE 802.1ah-2008. It aims to improve the scalability of Media Access Control (MAC) addresses and service instances in Provider Ethernet networ...

Targeting cyclin-dependent kinases in Drosophila with peptide aptamers.

Two-hybrid technology provides a simple way to isolate small peptide aptamers that specifically recognize and strongly bind to a protein of interest. These aptamers have the potential to dominantly interfere with specific activities of their target proteins and, therefore, could be used as in vivo inhibitors. Here we explore the ability to use peptide aptamers as in vivo inhibitors by expressin...